Product Details
| Alternative Name: | Lymphocyte activation gene-3, FDC protein, CD223 |
| |
| Clone: | 17B4 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | Synthetic peptide corresponding to 30 aa (GPPAAAPGHPLAPGPHPAAPSSWGPRPRRY) from the first N-terminal D1 domain of human LAG-3 (lymphocyte activation gene-3). |
| |
| UniProt ID: | P18627 |
| |
| Source: | Purified from hybridoma tissue culture supernatant. |
| |
| Species reactivity: | Human
|
| |
| Specificity: | Recognizes the 30 aa extra-loop of the first N-terminal D1 domain of LAG-3. |
| |
| Applications: | ELISA, WB
|
| |
| Recommended Dilutions/Conditions: | ELISA (detection)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Purity Detail: | Purified from concentrated hybridoma tissue culture supernatant by Protein A Sepharose™ CL-4B Flow Fast Column. |
| |
| Formulation: | Liquid. In PBS containing 50mM Tris-HCl, 1% BSA and 0.02% sodium azide. |
| |
| Use/Stability: | Stable for at least 6 months after receipt when stored as recommended. |
| |
| Handling: | Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | The lymphocyte activation gene-3 (LAG-3, CD223), a member of the immunoglobulin superfamily (IgSF) related to CD4, binds to the major histocompatibility complex (MHC) class II molecules but with higher affinity than CD4. Several alternative mRNA splice-variants of human LAG-3 have been described, two of them encoding potential secreted forms: LAG-3V1 (i.e. the D1-D2 domains of the protein, 36 kDa) and LAG-3V3 (D1-D3, 52 kDa). The longer form was detected by ELISA in the serum of healthy individuals as well as of tuberculosis patients with a favorable outcome. LAG-3 expression by T cell clones correlated with IFN-γ production, and hence soluble LAG-3 has been suggested as a serological marker of Th1 responses. |
| |
| Technical Info/Product Notes: | SEPHAROSE is a trademark of GE Healthcare companies. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Product Literature References
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response: A.C. Huang, et al.; Nature
545, 60 (2017),
Abstract;
Full Text
Human lymphocyte activation gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cell activation: C. Casati, et al.; J. Immunol.
180, 3782 (2008),
Abstract;
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors: F. Triebel, et al.; Cancer Lett.
235, 147 (2006),
Abstract;
Immunological mechanisms elicited at the tumour site by lymphocyte activation gene-3 (LAG-3) versus IL-12: sharing a common Th1 anti-tumour immune pathway: E.D. Carlo, et al.; J. Pathol.
205, 82 (2005),
Abstract;
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells: L. Macon-Lemaitre and F. Triebel; Immunology
115, 170 (2005),
Abstract;
T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3/MHC class II interactions in cell-cell contacts: C.E. Demeure, et al.; Eur. J. Cancer
37, 1709 (2001),
Abstract;
CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling: S. Hannier, et al.; J. Immunol.
161, 4058 (1998),
Abstract;
Full Text
Characterization of the major histocompatibility complex class II binding site on LAG-3 protein: B. Huard, et al.; PNAS
94, 5744 (1997),
Abstract;
Full Text
Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand: B. Huard, et al.; Immunogenetics
39, 213 (1994),
Abstract;
Characterization of the lymphocyte activation gene 3-encoded protein. A new ligand for human leukocyte antigen class II antigens: E. Baixeras, et al.; J. Exp. Med.
176, 327 (1992),
Abstract;
Full Text
Related Products
